Study To Evaluate The Pharmacokinetic Interaction Between PLA-695 And Methotrexate In Adults With Rheumatoid Arthritis

Completed · Phase 1

Conditions studied: Arthritis, Rheumatoid

In brief

The purpose of this study is to determine if PLA-695 changes the blood concentrations of methotrexate when administered together.

Key facts

Study ID

NCT00440492

Run by

Wyeth is now a wholly owned subsidiary of Pfizer

Starts

2006-12-01

Expected to finish

2007-11-01

Last updated by the study team

2007-12-13

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men or women of nonchildbearing potential with rheumatoid arthritis (RA), aged 18 to 75 years
• RA disease onset after 16 years of age and has had the disease for at least 6 months
• Must be receiving a stable, well-tolerated oral dose of methotrexate (5 to 25 mg) taken once weekly for at least 3 months

You may not qualify if…

• Evidence of unstable clinically significant disease

Where it is running

• Study site — Los Angeles, California, United States
• Study site — Palo Alto, California, United States
• Study site — Lake Success, New York, United States
• Study site — Rochester, New York, United States
• Study site — Charlotte, North Carolina, United States
• Study site — Columbus, Ohio, United States
• Study site — Vancouver, British Columbia, Canada
• Study site — Mississauga, Ontario, Canada
• Study site — Montreal, Quebec, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.